Preclinical CRO Market Size, Share, Trends, Growth Outlook

Preclinical CRO Market is estimated to increase at a growth rate of 8.5% CAGR over the forecast period from 2024 to 2032.

 

The Preclinical CRO Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Service (Bioanalysis and DMPK studies(In vitro ADME, In-vivo PK), Toxicology Testing(GLP, Non-GLP), Compound Management(Process R&D, Custom Synthesis, Others), Chemistry(Medicinal Chemistry, Computation Chemistry), Safety Pharmacology, Others), By Model Type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model), By End-user (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies).

An Introduction to Preclinical CRO Market in 2024

The Preclinical Contract Research Organization (CRO) Market is set to witness robust growth in 2024, driven by the increasing outsourcing of preclinical research activities by pharmaceutical, biotechnology, and medical device companies, rising investments in drug discovery and development, and the growing complexity of preclinical studies. Preclinical CROs offer a wide range of services, including pharmacology, toxicology, bioanalysis, safety assessment, and regulatory support, to assist biopharmaceutical companies in early-stage drug development, efficacy testing, safety evaluation, and regulatory submission.

Key factors contributing to the growth of the preclinical CRO market include the rising R&D costs, the need for specialized expertise and infrastructure, and the focus on accelerating drug development timelines while mitigating risks and costs. In addition, advancements in technology, such as high-throughput screening, in vitro models, and computational biology, enhance the efficiency, accuracy, and predictive value of preclinical studies, driving demand for CRO services. In addition, strategic collaborations, partnerships, and acquisitions among pharmaceutical companies and preclinical CROs aim to leverage complementary capabilities, resources, and expertise, thereby fostering innovation, scalability, and market expansion.

Moreover, increasing regulatory requirements, such as the need for comprehensive safety assessments, data integrity, and compliance with Good Laboratory Practice (GLP) standards, drive the outsourcing of preclinical research to specialized CROs with proven track records and regulatory expertise. In addition, the COVID-19 pandemic has underscored the importance of preclinical research in vaccine and therapeutics development, leading to increased investments in infectious disease research and drug repurposing efforts, further fueling market growth and opportunities for preclinical CROs.

Preclinical CRO Market Trend: Increasing Outsourcing of Preclinical Research Activities

A prominent trend in the preclinical CRO market is the increasing outsourcing of preclinical research activities by pharmaceutical and biotechnology companies. As drug discovery and development processes become more complex and resource-intensive, pharmaceutical companies are turning to contract research organizations (CROs) specializing in preclinical services to accelerate the drug development timeline and reduce costs. Outsourcing preclinical research allows pharmaceutical companies to access specialized expertise, state-of-the-art facilities, and a flexible workforce, enabling them to focus on core competencies such as drug discovery and clinical trials. This trend towards outsourcing preclinical research is expected to continue as pharmaceutical companies seek to optimize their research and development (R&D) processes and bring new drugs to market more efficiently.

Preclinical CRO Market Driver: Increasing R&D Expenditure in the Pharmaceutical and Biotechnology Industries

A significant driver in the preclinical CRO market is the increasing research and development (R&D) expenditure in the pharmaceutical and biotechnology industries. With a growing emphasis on innovation and the development of novel therapeutics to address unmet medical needs, pharmaceutical and biotechnology companies are investing heavily in R&D activities. However, the high cost and long timelines associated with drug discovery and development pose significant challenges to companies seeking to bring new drugs to market. Outsourcing preclinical research to CROs allows pharmaceutical and biotechnology companies to access specialized expertise and infrastructure without the need for substantial capital investment, thereby accelerating the drug development process and reducing overall R&D costs.

Preclinical CRO Market Opportunity: Expansion into Specialized Therapeutic Areas and Emerging Markets

An exciting potential opportunity in the preclinical CRO market lies in the expansion into specialized therapeutic areas and emerging markets. With the increasing complexity of drug development and the growing demand for specialized expertise in therapeutic areas such as oncology, neurology, and rare diseases, there is significant demand for preclinical CROs with expertise in these areas. By expanding their service offerings to cater to specialized therapeutic areas and investing in capabilities such as disease models, biomarker analysis, and translational research, preclinical CROs can differentiate themselves in the market and capture opportunities for growth. Additionally, there is substantial potential for market expansion in emerging markets, where pharmaceutical R&D activity is increasing, and regulatory environments are becoming more favorable. By establishing a presence in emerging markets and offering tailored preclinical research services, CROs can tap into new sources of revenue and drive growth in the preclinical CRO market.

Preclinical CRO Market Segmentation

By Service

• Bioanalysis and DMPK studies

-In vitro ADME
-In-vivo PK

• Toxicology Testing

-GLP
-Non-GLP

• Compound Management

-Process R&D
-Custom Synthesis
-Others

• Chemistry

-Medicinal Chemistry
-Computation Chemistry

• Safety Pharmacology
• Others

By Model Type

• Patient Derived Organoid (PDO) Model
• Patient derived xenograft model

By End-user

• Biopharmaceutical Companies
• Government and Academic Institutes
• Medical Device Companies

Geographical Analysis

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
• Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
• South America (Brazil, Argentina, Rest of South America)
• Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Preclinical CRO Market Companies

• Charles River Laboratories International, Inc.
• Crown Bioscience
• Eurofins Scientific
• Intertek Group Plc (IGP)
• LABCORP
• Medpace, Inc.
• PRA Health Sciences, Inc.
• PPD (Thermo Fisher Scientific, Inc.)
• SGA SA
• Wuxi AppTec

 

Reasons to Buy the Preclinical CRO Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Preclinical CRO Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Preclinical CRO Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Preclinical CRO Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Preclinical CRO Market Size Outlook, $ Million, 2021 to 2030
3.2 Preclinical CRO Market Outlook by Type, $ Million, 2021 to 2030
3.3 Preclinical CRO Market Outlook by Product, $ Million, 2021 to 2030
3.4 Preclinical CRO Market Outlook by Application, $ Million, 2021 to 2030
3.5 Preclinical CRO Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Preclinical CRO Market Industry
4.2 Key Market Trends in Preclinical CRO Market Industry
4.3 Potential Opportunities in Preclinical CRO Market Industry
4.4 Key Challenges in Preclinical CRO Market Industry
5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Preclinical CRO Market Share by Company
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Preclinical CRO Market Outlook By Segments
7.1 Preclinical CRO Market Outlook by Segments
By Service
Bioanalysis and DMPK studies
-In vitro ADME
-In-vivo PK
Toxicology Testing
-GLP
-Non-GLP
Compound Management
-Process R&D
-Custom Synthesis
-Others
Chemistry
-Medicinal Chemistry
-Computation Chemistry
Safety Pharmacology
Others

By Model Type
Patient Derived Organoid (PDO) Model
Patient derived xenograft model

By End-user
Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

8 North America Preclinical CRO Market Analysis And Outlook To 2030
8.1 Introduction to North America Preclinical CRO Markets in 2024
8.2 North America Preclinical CRO Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Preclinical CRO Market size Outlook by Segments, 2021-2030
By Service
Bioanalysis and DMPK studies
-In vitro ADME
-In-vivo PK
Toxicology Testing
-GLP
-Non-GLP
Compound Management
-Process R&D
-Custom Synthesis
-Others
Chemistry
-Medicinal Chemistry
-Computation Chemistry
Safety Pharmacology
Others

By Model Type
Patient Derived Organoid (PDO) Model
Patient derived xenograft model

By End-user
Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

9 Europe Preclinical CRO Market Analysis And Outlook To 2030
9.1 Introduction to Europe Preclinical CRO Markets in 2024
9.2 Europe Preclinical CRO Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Preclinical CRO Market Size Outlook By Segments, 2021-2030
By Service
Bioanalysis and DMPK studies
-In vitro ADME
-In-vivo PK
Toxicology Testing
-GLP
-Non-GLP
Compound Management
-Process R&D
-Custom Synthesis
-Others
Chemistry
-Medicinal Chemistry
-Computation Chemistry
Safety Pharmacology
Others

By Model Type
Patient Derived Organoid (PDO) Model
Patient derived xenograft model

By End-user
Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

10 Asia Pacific Preclinical CRO Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Preclinical CRO Markets in 2024
10.2 Asia Pacific Preclinical CRO Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Preclinical CRO Market size Outlook by Segments, 2021-2030
By Service
Bioanalysis and DMPK studies
-In vitro ADME
-In-vivo PK
Toxicology Testing
-GLP
-Non-GLP
Compound Management
-Process R&D
-Custom Synthesis
-Others
Chemistry
-Medicinal Chemistry
-Computation Chemistry
Safety Pharmacology
Others

By Model Type
Patient Derived Organoid (PDO) Model
Patient derived xenograft model

By End-user
Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

11 South America Preclinical CRO Market Analysis And Outlook To 2030
11.1 Introduction to South America Preclinical CRO Markets in 2024
11.2 South America Preclinical CRO Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Preclinical CRO Market size Outlook by Segments, 2021-2030
By Service
Bioanalysis and DMPK studies
-In vitro ADME
-In-vivo PK
Toxicology Testing
-GLP
-Non-GLP
Compound Management
-Process R&D
-Custom Synthesis
-Others
Chemistry
-Medicinal Chemistry
-Computation Chemistry
Safety Pharmacology
Others

By Model Type
Patient Derived Organoid (PDO) Model
Patient derived xenograft model

By End-user
Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

12 Middle East And Africa Preclinical CRO Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Preclinical CRO Markets in 2024
12.2 Middle East and Africa Preclinical CRO Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Preclinical CRO Market size Outlook by Segments, 2021-2030
By Service
Bioanalysis and DMPK studies
-In vitro ADME
-In-vivo PK
Toxicology Testing
-GLP
-Non-GLP
Compound Management
-Process R&D
-Custom Synthesis
-Others
Chemistry
-Medicinal Chemistry
-Computation Chemistry
Safety Pharmacology
Others

By Model Type
Patient Derived Organoid (PDO) Model
Patient derived xenograft model

By End-user
Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Charles River Laboratories International, Inc.
Crown Bioscience
Eurofins Scientific
Intertek Group Plc (IGP)
LABCORP
Medpace, Inc.
PRA Health Sciences, Inc.
PPD (Thermo Fisher Scientific, Inc.)
SGA SA
Wuxi AppTec

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

Preclinical CRO Market Segmentation

By Service

• Bioanalysis and DMPK studies

-In vitro ADME
-In-vivo PK

• Toxicology Testing

-GLP
-Non-GLP

• Compound Management

-Process R&D
-Custom Synthesis
-Others

• Chemistry

-Medicinal Chemistry
-Computation Chemistry

• Safety Pharmacology
• Others

By Model Type

• Patient Derived Organoid (PDO) Model
• Patient derived xenograft model

By End-user

• Biopharmaceutical Companies
• Government and Academic Institutes
• Medical Device Companies

Geographical Analysis

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
• Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
• South America (Brazil, Argentina, Rest of South America)
• Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)